Many studies have connected epigenomic changes to substance abuse disorders. However, there is a key barrier to our understanding of the epigenome?s mechanistic roles. While epigenomic modifications have been widely mapped and correlated with changes in gene expression and cellular phenotypes, correlation does not demonstrate function or causation. This barrier arises because widely used techniques to perturb the epigenome, including pharmacological inhibition and genetic knock-outs or overexpressions, suffer from pleiotropic effects. Thus, it is unclear if epigenomic modifications drive, are a result of, or are simply associated with changes in gene states. Two important corollaries arise from this: 1) It is unclear whether and which epigenome modifications drive changes in gene expression, and 2) the temporal stability of epigenome modifications that would result in truly persistent ?epigenetic? properties is unknown. The hypothesis of the proposed work is that the epigenome represents a powerful regulatory system layered on top of the genome, and by engineering new tools to interface with and control this system, we can harness its unique properties to understand and tackle substance abuse disorders. A guiding goal is to dissect the function of epigenome modifications from their form and demonstrate their specific relevance to substance abuse disorders. To achieve this, we will develop tools to sense and induce changes in the epigenome, and do so spatiotemporally in systems reflective of human genetics, epigenetics, and physiology.

Public Health Relevance

The epigenome presents an intriguing substrate on which persistent changes in cellular responses could be stored. Thus, it may hold a key role in the mechanisms of addiction and substance abuse disorders. However, it remains difficult to distinguish whether changes in the epigenome are simply correlative or truly functional in driving addiction. Here we propose a new class of synthetic tools to distinguish epigenomic form from function in the study of substance abuse disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
NIH Director’s Pioneer Award (NDPA) (DP1)
Project #
1DP1DA044359-01
Application #
9376441
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Pollock, Jonathan D
Project Start
2017-09-01
Project End
2022-08-31
Budget Start
2017-09-01
Budget End
2018-08-31
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
North Carolina State University Raleigh
Department
Engineering (All Types)
Type
Biomed Engr/Col Engr/Engr Sta
DUNS #
042092122
City
Raleigh
State
NC
Country
United States
Zip Code
27695
Lee, Jessica B; Keung, Albert J (2018) Chromatin Immunoprecipitation in Human and Yeast Cells. Methods Mol Biol 1767:257-269
Sen, Dilara; Keung, Albert J (2018) Designing Epigenome Editors: Considerations of Biochemical and Locus Specificities. Methods Mol Biol 1767:65-87